



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: ORLOW1A

In re Application of: Seth ORLOW et al. Conf. No.: 3666

Appln. No.: 10/821,981

Art Unit: 1615

Filing Date: April 12, 2004

Examiner:

For: COMPOUNDS FOR STIMULATING AND FOR INHIBITING MELANIN...

Washington, D.C. February 28, 2005

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents U.S. Patent and Trademark Office Customer Service Window Randolph Building, Mail Stop Amendment 401 Dulany Street Alexandria, VA 22314

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §\$1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

- [X] 1. This IDS should be considered, in accordance with 37 CFR \$1.97, as it is filed:
- [] A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.
- [X] B. before the mailing date of a first office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 CFR \$1.114; or

[] C. after (A) and (B) above, but before final
rejection or allowance, and Applicant has made the necessary
certification (box "i" below) or paid the necessary fee (box
"ii" below):
[] i. Counsel certifies that, upon information and belief, each item of information listed herein either was
(a) first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
[] (b) not cited in a communication from a

- [] (b) not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, not known to any individual designated in 37 CFR \$1.56(c) more than three months prior to the filling of this IDS.
- [] ii. Credit Card Payment Form, PTO-2038, is attached authorizing payment of the fee set forth in 37 CFR §1.17(p), presently believed to be \$180. If the enclosed payment is incorrect, please charge any additional fees or credit any overpayment to Deposit Account No. 02-4035 of the undersigned.
- [X] 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form BN/SB/08A/B) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. Other than U.S. patent(s) and/or published U.S. application(s), which 37 CFR §1.98(a)(2)(ii) does not require to be filed unless specifically required by the Office, a copy of each document listed is attached, except as explained below:

[]	A. Document(s)	is/are	deemed
substantially	cumulative to document(s)		, and

states:

in accordance with	37	CFR	§1.98(c),	а	сору	of	each	of	the
former document(s)	is	not	enclosed.						

[] B. Certain documents were previously cited by or submitted to the Office in the following prior application(s), which are relied upon under 35 U.S.C. 120:

(insert serial numbers and filing dates of prior applications) Applicant identifies these documents by attaching hereto copies of the forms PTO-892, PTO-1449, PTO/SB/08a and/or PTO/SB/08b (or their BN form equivalents) from the files of the prior application(s) or a fresh BN/SB/08A and/or BN/SB/08B listing these documents, and request that they be considered and made of record in accordance with 37 CFR \$1.98(d). Per 37 CFR \$1.98(d), copies of these documents need not be filed in this application.

[] 3. Document(s) ____ is/are not in the English

language. In accordance with 37 CFR \$1.98(a)(3), Applicant [] An English translation of each document ____ (or of the pertinent portions thereof), or a copy of an English-language abstract (or claim) is enclosed. [] For documents _____, a corresponding English-language patent or published application is included on the accompanying Form BN/SB/08A, with a line drawn in the margin connecting the non-English-language document with its corresponding English-language document. [] A concise explanation of the relevance of document(s) _____ is found in the attached search report (see reply to Comment 68 in the preamble to the final rules; 1135 OG 13 at 20). [] A concise explanation of the relevance of document(s) _____ is set forth as follows:

ĺ]	A concise explanation	of the	relevance of
		document(s)	can be	found on page(s)
		of the specif	icatio	n.
Į	1	A concise explanation	of the	relevance of
		document(s)	can be	found on the
		attached sheet.		

- [X] 4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).
- $\ensuremath{\left[\mathrm{X}\right]}$ 5. Other information being provided for the examiner's consideration follows:

International Search Report

6. In accordance with 37 CFR §\$1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK

Attorneys for Applicant(s

Bv:

Sheridan Néimark Registration No. 20,520

SN:lmh

624 Ninth Street, N.W., Suite 300

Washington, D.C. 20001-5303 Telephone: (202)628-5197

Facsimile: (202) 628-5197

G:\BN\N\nyum\ORLOW 1A\pto\ids.feeFEB2005.doc



Substitute form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Co	mplete if Known	
Application Number	10/821,981	
Filing Date	April 12, 2004	
First Named Inventor	Seth ORLOW	
Group Art Unit	1615	
Examiner Name		
Attorney Docket Number	OBLOWIA	

	U.S. PATENT DOCUMENTS							
Examiner nitials*	Cite No.1	Document Number Number-Kind Code ^{2 pt} known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
		US-						
		us.						
		US-						
		US-		-				
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Number Country Code* Number* Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶	
/C.B./	AM	WO 02/085349 A1	10-31-02	Beiersdorf AG			
/C.B./	AN	WO 02/098347 A2	12-12-2002	New York University			
						_	

Examiner Signature	/Courtney Brown/	Date Considered	11/27/2007

^{*}EXAMINET: Initial if reference consistents, whether or not distain is in conformance with IMPEG 698. Dow the through cisition if not in conformance and not considered. Include copy of this form with not communication is papient.** Papients usuage citation designation number (opinion). "See Kind Codes of USFTO Platent Documents as year, as yea

THE 28 MILES

stitute for form 1449A/PTO

Examiner

Signature

/Courtney Brown/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 2 of 2

Co	mplete if Known	
Application Number	10/821,981	
Filing Date	April 12, 2004	
First Named Inventor	Seth ORLOW	
Group Art Unit	1615	
Examiner Name		
Attorney Docket Number	ORLOW1A	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-assue number(s), publisher, city and/or country where published	T ²
/C.B./		HU D-N et al., "Regulation of Melanogenesis by Human Unveal Melanocytes in Vitro", Chemical Abstracts, (June 23, 1997), Vol. 126, No. 25, abstract only.	
/C.B.	AP	Greenspan A.H. et al., "Acanthosis Nigricans-like Hyperpigmentation Secondary to Triazinate Therapy", Archives of Dermatology, Feb. 1985), Vol. 121, No. 2, pp. 232-235, XP009037865.	
/C.B	1	Knockaert M. et al., "Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors", Chemistry and Biology, (June 2000), Vol. 7, No. 6, pp. 411–422, XP001070114.	
/C.B		Mårs U. et al., "New Thioureas and Related Substances Intended for Melonoma Targeting", Pigment Cell Research, (Aug. 1995), Vol. 8, No. 4, pp. 194-201, XP009037885.	
/C.B	/	Silen J. L. et al., "Screening for Novel Antimicrobials from Encoded Combinatorial Libraries by Using a Two- Dimensional Agar Format", Antimicrobial Agents and Chemotherapy, (June 1998), Vol.42, No. 6, pp. 1447-1753, XP	

Date

Considered

11/27/2007

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.